

THURSDAY
5th JUNE
2025

afpbn

ASSOCIATION FRANÇAISE
DE PSYCHIATRIE BIOLOGIQUE
NEUROPSYCHOPHARMACOLOGIE

afpbn

section
médecine
psychédélique

PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

Organizing Committee :

Dr. Lucie Berkovitch

Dr. Hugo Bottemanne

Prof. Luc Mallet

Dr. Bruno Roméo

ICM - Institut du Cerveau

Hôpital Pitié-Salpêtrière
47 bd de l'Hôpital, 75013 Paris

Soutenu
par le



GOUVERNEMENT

Liberté
Égalité
Fraternité

MILDECA

Mission interministérielle
de lutte contre les drogues
et les conduites addictives

PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

8:45 AM: Welcome

9:00 AM: Introduction - Bureau of the Psychedelic Medicine Section

09:15–10:00 AM: Pharmacology of psychedelics: similarities and differences - Matthias Liechti, Basel University

Chair : Carine Becamel, Montpellier

10:00–10:45 AM: Psychedelic therapies - How do they seem to differ from existing treatments in mental health?

David Erritzoe, Imperial College of London

Chair : Anne Claret, Paris

10:45 –11:00 AM: Coffee Break

11:00 –11:45 AM: Mechanisms of psychedelics in the treatment of alcohol dependence - Mickael Naassila, University of Picardy

Chair : Alain Gardier, Chatenay-Malabry

11:45–12:30 AM: Are the neurobiological properties of psychedelics predictive of therapeutic effects in addiction?

Christian Lüscher, University of Geneva

Chair : Marc Gielen, Créteil

12:30–1:30 PM: Lunch Break

PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

1:30 –2:00 PM: Processes and challenges in setting up a psilocybin study in France: example of the first French study (PAD)

Amandine Luquiens, CHU Nîmes

Chair : Jérôme Jeanblanc, Amiens

2:00–2:45 PM: Global brain effects of psychedelics and therapeutic implications

Katrin Preller, University Hospital for Psychiatry, Zurich

Chair : Baptiste Fauvel, Paris

2:45–3:30 PM: LSD in the treatment of mood and anxiety disorders

Frederike Holze, Basel University

Chair : Alexandre Alt, Genève

3:30–3:45 PM: Coffee Break

3:45 –4:30 PM: Psilocybin as a catalyst for psychotherapy ? Insights from the German EPIsoDE Trial

Lea Mertens, Central Institute of Mental Health, University of Heidelberg

Chair : Laetitia Vanderijst, Bruxelles

4:30–5:15 PM: Prospects on the use of psychedelic treatments as antidepressant therapy

Guy Goodwin, COMPASS Pathways, London

Chair : Mickael Koslowski, Berlin

5:15–5:30 PM: Closing Remarks, Bureau of the Psychedelic Medicine Section

PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

afpbn
section
médecine
psychédélique



SCANNEZ LE QR CODE POUR VOUS INSCRIRE !

AGENCE PCO : COM'TO EVIDENCE

www.comtoevidence.com



**COM'TO
EVIDENCE**

CONTACT :

Mathias BRACCHETTI-GRANET

Email : contact@comtoevidence.com

Tél. : 33 (0)9 81 25 85 82